News

Related Publications

News

Press release 03/16/2010

NeuroPhage Adds Seasoned Executives to the Board of Directors

Mark Skaletsky and Paul Goldenheim Join Board of Directors

CAMBRIDGE, Mass. – March 16, 2010 – NeuroPhage Pharmaceuticals, Inc., a privately held biotechnology company advancing novel approaches for the treatment of neurodegenerative diseases, announced today that it has extended the board of directors with two seasoned executives: Mark Skaletsky is joining as Executive Chairman and Paul Goldenheim, M.D. as a director.

Skaletsky was previously President, Chairman and Chief Executive Officer of Trine Pharmaceuticals, Inc., and President and Chief Executive Officer of GelTex Pharmaceuticals, Inc., which was acquired by Genzyme in 2000.  Prior to GelTex, he served as Chairman and Chief Executive Officer of Enzytech and as President and Chief Operating Officer of Biogen. Mark currently serves on the Boards of Directors of ImmunoGen, Alkermes, Targacept and Cerenis and is former Chairman of Domantis (sold to GlaxoSmithKline) and of the Biotechnology Industry Organization (BIO).

Goldenheim serves on the boards of directors of several companies, including Alinea, Promedior, and Hydra Biosciences, and serves as a consultant to several others. He has a 25-year history in pharmaceutical research, development, and management most recently as President of TransForm Pharmaceuticals (acquired by Johnson & Johnson) and Vice-Chairman of the Board of Directors of Hypnion (sold to Eli Lilly). Paul has authored numerous scientific publications and been an inventor on a number of pharmaceutical patents.  He received his A.B. from Harvard College magna cum laude with highest honors in biochemical sciences and his M.D. from Harvard Medical School.

About NeuroPhage

NeuroPhage is advancing a disease-modifying phage-based approach targeted at Alzheimer's, Parkinson's and other neurodegenerative diseases.  NeuroPhage was founded in 2006 by Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University and pioneer of immunotherapy for Alzheimer’s, together with a Cambridge-based entrepreneurial team.  NeuroPhage has raised a total of $10.8 million in equity and convertible debt financings to date from private investors.  NeuroPhage is based in Cambridge, MA.